profit from every $100 of sales.
$0$100
Royalty Pharma
$69.31+0.49% today
+74.5% in 1 year
1-year low $38.091-year high $70.01
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $51.69 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Royalty Pharma sold, what it kept, and what it did with the cash.
Sales went from $2.24 billion in 2022 to $2.38 billion in 2025, with $771 million of profit last year.
SalesProfit
Royalty Pharma handed back 64% of the cash it generated last year.
Buybacks $1.2B$378M
Free cash flow 2025$2.5B
Bought back its own shares$1.2B
Paid as dividends$378M
Cash vs. debt$619M vs. $9.0B
Royalty Pharma vs. similar companies
Royalty Pharma grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Royalty Pharma | 51.7× · Expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Royalty Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,122 | 2,289 | 2,237 | 2,355 | 2,264 | 2,378 | |
| – | – | – | – | – | – | |
| 1,595 | 1,431 | 923 | 1,492 | 1,292 | 1,560 | |
| – | – | 424 | 1,887 | 1,556 | 1,636 | |
| 975 | 620 | 43 | 1,135 | 859 | 771 | |
| – | – | 0.10 | 2.53 | 1.45 | 1.37 | |
| – | – | – | – | – | – | |
| 75.2% | 62.5% | 41.3% | 63.4% | 57.1% | 65.6% | |
| 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 16,020 | 17,516 | 16,813 | 16,382 | 18,223 | 19,621 |
| Cash | 1,009 | 1,541 | 1,711 | 477 | 929 | 619 |
| Total debt | 5,817 | 7,096 | 7,116 | 6,135 | 7,612 | 8,951 |
| Total liabilities | 6,124 | 7,267 | 7,288 | 6,298 | 7,880 | 9,906 |
| – | – | 5,628 | 6,526 | 6,947 | 6,477 | |
| 375 | 415 | 438 | 603 | 594 | 564 | |
| – | – | 2.6% | 11.8% | 8.4% | 8.4% | |
| – | – | 0.8% | 17.4% | 12.4% | 11.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,035 | 2,018 | 2,144 | 2,988 | 2,769 | 2,490 | |
| – | – | – | – | – | – | |
| – | – | 2,144 | 2,988 | 2,769 | 2,490 | |
| Dividends paid | – | – | 333 | 358 | 376 | 378 |
| 0 | 0 | 0 | 305 | 230 | 1,227 | |
| 5 | 2 | 2 | 2 | 2 | 290 |
Valuation
- 51.7×
- 14.2×
- –
- 6.0×
- 16.8×
- 16.0×
- 29.5×
- 6.2%
- 1.9%
- 1.7%
Profitability
- 100.0%
- 65.6%
- 32.4%
- 72.5%
- 8.6%
- 8.0%
- 12.7%
- 4.2%
- 8.6%
- 18.1%
Growth
- +2.3%
- –
- −10.1%
- +24.0%
- +8.8%
Financial health
- 5.1×
- 1.38
- 45.2%
- 5.3×
- 2.40
- 2.66
- 0.12
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 35%of 952
Top 1%of 884
Bottom 21%of 601
Bottom 22%of 886
Top 16%of 987
What analysts expect
- Average price target
- $53.75
- Range
- $45.00 – $63.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 1.30 | 1.22 | +6.6% |
| Feb 11, 2026 | 1.46 | 1.29 | +13.2% |
| Nov 5, 2025 | 1.17 | 0.99 | +17.7% |
| Aug 6, 2025 | 1.14 | 1.03 | +10.7% |
| May 8, 2025 | 1.06 | 0.95 | +11.2% |
| Feb 11, 2025 | 1.15 | 0.99 | +16.2% |
| Nov 6, 2024 | 1.04 | 0.93 | +12.1% |
| Aug 8, 2024 | 0.96 | 0.97 | −0.5% |
1.7%of the share price, paid each year
On $1,000 invested$17a year at today's yield, before tax
+24.0%2020 to 2025
Raised5 yearsin a row, in our data
Paid per share, each year
$0.30 in 2020 → $0.88 in 2025
How safe it looks
49.1% of its profit
Room to growStretchedMore than it earns: 15.2%
News
Arm Sinks 9% as Royalty Growth Slows to “Low Single Digits” on Smartphone WeaknessYahoo Finance · Nov 5, 2026Royalty Pharma plc Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 2026Crescent Energy files for proposed IPO of royalty subsidiarySeeking Alpha · Nov 2, 20263 Reasons Royalty Pharma Is a Dividend Stock You Never Have to SellYahoo Finance · Oct 22, 2026Dorchester Minerals to acquire 4,300 net royalty acres in North DakotaSeeking Alpha · Oct 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
41No pass
Philip Fisher
39No pass
Peter Lynch
54No pass
Joel Greenblatt
13No pass
Charlie Munger
37No pass
Terry Smith
43No pass
Questions about Royalty Pharma
Is Royalty Pharma a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Royalty Pharma AI analysis
What does Royalty Pharma do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. It is in Biotechnology, based in New York, NY, United States, with 100 employees.
Does Royalty Pharma pay a dividend?
Yes. At today's price the dividend is 1.7% a year, about 49% of its yearly profit. In 2025 it paid out $378 million in dividends.
Is Royalty Pharma stock halal?
Yes. Royalty Pharma passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has Royalty Pharma stock done over the past year?
Up 74.5% over the past twelve months, to $69.31. It traded between $38.09 and $70.01, close to its high.
Who are Royalty Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Royalty Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.